相似文献/References:
[1]刘子扬,叶俊杰.息肉状脉络膜血管病变并发玻璃体积血的机制研究[J].眼科新进展,2016,36(2):193.[doi:10.13389/j.cnki.rao.2016.0053]
LIU Zi-Yang,YE Jun-Jie.Research on mechanism of polypoidal choroidal vasculopathy combined with vitreous hemorrhage[J].Recent Advances in Ophthalmology,2016,36(12):193.[doi:10.13389/j.cnki.rao.2016.0053]
[2]刘子扬,夏松,杨景元,等.息肉状脉络膜血管病变抗血管内皮生长因子（VEGF）治疗后1年的视力预后与基线特征的相关性分析[J].眼科新进展,2018,38(5):440.[doi:10.13389/j.cnki.rao.2018.0102]
LIU Zi-Yang,XIA Song,YANG Jing-Yuan,et al.Correlation of 1-year vision outcomes with baseline factors in polypoidal choroidal vasculopathy patients after anti-VEGF treatment[J].Recent Advances in Ophthalmology,2018,38(12):440.[doi:10.13389/j.cnki.rao.2018.0102]
[3]刘子扬,陈有信.息肉状脉络膜血管病变的危险因素分析[J].眼科新进展,2018,38(6):538.[doi:10.13389/j.cnki.rao.2018.0125]
LIU Zi-Yang,CHEN You-Xin.Ocular risk factors for polypoidal choroidal vasculopathy[J].Recent Advances in Ophthalmology,2018,38(12):538.[doi:10.13389/j.cnki.rao.2018.0125]
[4]刘华,许多,陈艳丽,等.康柏西普治疗息肉状脉络膜血管病变的临床疗效[J].眼科新进展,2018,38(12):1144.[doi:10.13389/j.cnki.rao.2018.0270]
LIU Hua,XU Duo,CHEN Yan-Li,et al.Clinical efficacy of conbercept in the treatment of polypoidal choroidal vasculopathy[J].Recent Advances in Ophthalmology,2018,38(12):1144.[doi:10.13389/j.cnki.rao.2018.0270]
[5]原铭贞,陈有信.息肉状脉络膜血管病变的基因研究进展[J].眼科新进展,2019,39(2):187.[doi:10.13389/j.cnki.rao.2019.0043]
YUAN Ming-Zhen,CHEN You-Xin.Advance research on genes of polypoidal choroidal vasculopathy[J].Recent Advances in Ophthalmology,2019,39(12):187.[doi:10.13389/j.cnki.rao.2019.0043]
[6]韩珺琳,张桐梅,解世勇,等.光动力疗法联合抗血管内皮生长因子治疗息肉状脉络膜血管病变的效果：基于光学相干断层扫描血管成像（OCTA）的观察[J].眼科新进展,2019,39(4):358.[doi:10.13389/j.cnki.rao.2019.0081]
HAN Jun-Lin,ZHANG Tong-Mei,XIE Shi-Yong,et al.Observation of photodynamic laser combined with anti-vascular endothelial growth factor in the treatment of polypoidal choroidal vasculopathy with optical coherence tomography[J].Recent Advances in Ophthalmology,2019,39(12):358.[doi:10.13389/j.cnki.rao.2019.0081]
[7]李凤媚,宋艳萍.康柏西普玻璃体内重复注射治疗息肉状脉络膜血管病变疗效及相关因素分析[J].眼科新进展,2019,39(10):969.[doi:10.13389/j.cnki.rao.2019.0221]
LI Feng-Mei,SONG Yan-Ping.Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy and its related factors[J].Recent Advances in Ophthalmology,2019,39(12):969.[doi:10.13389/j.cnki.rao.2019.0221]
[8]王海燕,王雨生.值得关注的肥厚型脉络膜病变[J].眼科新进展,2020,40(3):201.[doi:10.13389/j.cnki.rao.2020.0048]
WANG Haiyan,WANG Yusheng.Pachychoroidopathy: a novel subject deserving of deep exploration[J].Recent Advances in Ophthalmology,2020,40(12):201.[doi:10.13389/j.cnki.rao.2020.0048]
[9]文峰,苏永悦.息肉状脉络膜血管病变的新术语和非基于吲哚菁绿血管造影的诊断标准——2021亚太眼科影像学会专家共识解读与思考[J].眼科新进展,2022,42(6):421.[doi:10.13389/j.cnki.rao.2022.0086]
WEN Feng,SU Yongyue.Interpretation of the consensus on nomenclature and non-indocyanine green angiograph based diagnostic criteria of polypoidal choroidal vasculopathy from the Asia-Pacific Ocular Imaging Society in 2021[J].Recent Advances in Ophthalmology,2022,42(12):421.[doi:10.13389/j.cnki.rao.2022.0086]